Detalhe da pesquisa
1.
A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer.
Int J Gynecol Cancer
; 27(2): 258-266, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27870712
2.
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
Int J Gynecol Cancer
; 26(9): 1580-1585, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27654255
3.
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Gynecol Oncol
; 127(1): 63-9, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22772063
4.
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Int J Cancer
; 127(9): 2209-21, 2010 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20473913
5.
Retrospective Analysis of Intravaginal Brachytherapy in Adjuvant Treatment of Early Endometrial Cancer.
Biomed Res Int
; 2018: 7924153, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29682556
6.
Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer.
Anticancer Res
; 35(3): 1715-21, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25750333
7.
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
J Clin Oncol
; 31(35): 4400-6, 2013 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24127448
8.
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
J Clin Oncol
; 30(31): 3841-7, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22987083